All patients received melphalan (0.2 mg/kg/d) plus prednisone (2 mg/kg/d) for 12 courses (day 1 to 4) every 6 weeks. Patients were randomly assigned to receive 100 mg/d of oral thalidomide (n = 113) ...

The combination of bortezomib, melphalan, and prednisone is a standard treatment for patients with newly diagnosed multiple myeloma who are ineligible for autologous stem-cell transplantation.

1 Randomized trials have shown that a course of high-dose melphalan (HDM) (140 or 200 mg/m 2) achieves a complete response in approximately 40% of patients, and that a second course enhances the ...

Melphalan HCl 50mg/vial; pwd for IV infusion after reconstitution and dilution. Melphalan is an alkylating agent with cytotoxic action that appears to be related to the extent of its interstrand ...

Oral melphalan and dexamethasone (MDex) is a standard treatment for patients with AL amyloidosis who are not eligible for stem cell transplantation at many referral centers. However, following ...

This was an investigator-initiated, multicenter, randomized, controlled, open-label clinical trial aimed to assess the efficacy of BMDex compared with MDex in previously untreated patients with AL ...

The standard treatment for patients with multiple myeloma who are not candidates for high-dose therapy is melphalan and prednisone. This phase 3 study compared the use of melphalan and prednisone ...

Serious adverse events occurred in 51.2 and 21.9% of patients receiving melphalan/hepatic delivery system and BAC, respectively. HealthDay News — For patients with unresectable metastatic uveal ...

Evidence-based recommendations on melphalan chemosaturation with percutaneous hepatic artery perfusion and hepatic vein isolation for primary or metastatic cancer in the liver. This involves diverting ...

Spectrum Pharmaceuticals is taking over the effort to develop and commercialize Ligand Pharmaceuticals’ Captisol®-enabled, propylene glycol-free (PG-free) melphalan as part of a potentially $53 ...